EuroIntervention | The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

Your reference journal for coronary, valvular and structural interventions

Original Research

Jul 2

Alessandro Beneduce, Dariusz Dudek, et al.

This ex vivo study evaluated the feasibility and outcomes of chimney stenting during redo-TAVI, finding that interactions between the coronary stents and the index TAV frames or aortic wall led to stent distortion and underexpansion, which could compromise procedural efficacy and future coronary access.

Letter to the Editor

Jul 4

REPLY: Completeness or complexity?

Claudio Laudani, Davide Capodanno, et al.

This manuscript discusses the challenges in assessing the impact of complete revascularization in STEMI patients, highlighting the limitations of available data and the importance of considering disease complexity.

free

Letter to the Editor

Jul 3

LETTER: Completeness or complexity?

Alessandro Sticchi, Giuseppe Biondi-Zoccai

The study by Laudani et al. examined complete revascularization strategies in acute myocardial infarction with multivessel disease, but the authors raise concerns about the potential dilution or exaggeration of true treatment effects due to heterogeneous trial designs and patient populations.

free

Research Correspondence

Jun 27

Next-day discharge following TAVI via alternative access

Yohanna John Zendo, Rodrigo Bagur, et al.

This study found that next-day and 48-hour discharge following alternative access transcatheter aortic valve implantation were safe, with similar 30-day outcomes in terms of readmissions and mortality, supporting the expansion of these early discharge pathways for all TAVI patients.

Next-day discharge following TAVI via alternative access

#EIJonAir

Jun 30

#EIJOnAir - Leaflet modification techniques during TAVI

Don't miss our upcoming live X video chat on Leaflet modification techniques to mitigate coronary obstruction risk during transcatheter aortic valve implantation with Sunny Goel and Alessandro Sticchi.

Join us live on our social media channels Wednesday 2 July at 5:30 PM (CET - Paris time).

#EIJOnAir - Leaflet modification techniques during TAVI

Expert Consensus

Jun 25

Antithrombotics and ACS in women

Valeria Paradies, Jolanta M. Siller-Matula, et al.

This article highlights the need for increased awareness of sex-specific risks and biases in the management of acute coronary syndrome, with a focus on sex-specific bleeding mitigation strategies, appropriate antithrombotic management, and improving female representation in cardiovascular trials.

open access

Original Research

Jun 23

Pacemaker implantation in TAVI for AR

Hendrik Wienemann, Matti Adam, et al.

This retrospective study found that 24.1% of patients without prior pacemaker required new permanent pacemaker implantation after transcatheter aortic valve implantation with the JenaValve Trilogy System for aortic regurgitation, with pre-existing conduction disturbances as independent predictors.

Original Research

Jun 20

Short DAPT in HBR patients with diabetes

Angelo Oliva, Roxana Mehran, et al.

This content covers various interventional procedures and therapies used in cardiology, including coronary, valvular, heart failure, peripheral, hypertension, and stroke interventions.

Short DAPT in HBR patients with diabetes

Meet Cory, your AI Assistant!

Enhance your reading experience and get deeper insights on complex topics.

Learn more

Jun 19

EuroIntervention's Impact Factor

We are pleased to share that EuroIntervention has achieved a new Impact Factor of 9.5, the highest in its 20-year history, confirming its place in the top quartile of cardiovascular publications with a ranking of 16 among 230 cardiology journals. This notable rise reflects the high standards of the Editorial Board and the ongoing contributions of our authors, reviewers, and readers.

Debate

Jun 18

Should QFR guidelines change?

William F. Fearon, Simone Biscaglia

The content discusses the use of quantitative flow ratio (QFR), a non-invasive angiography-derived tool, for the assessment of intermediate coronary stenoses, and the ongoing debate on its performance compared to fractional flow reserve (FFR).

NEW ISSUE

Jun 16

A new issue of EuroIntervention

In this issue of EuroIntervention, there is an expert consensus from the EAPCI and the ESC Working Group on Thrombosis on antithrombotics and ACS in women. This issue also includes a debate on the current quantitative flow ratio guidelines. In original research, we look at short dual antiplatelet therapy in high bleeding risk patients with diabetes, pacemaker implantation in TAVI for aortic regurgitation, and chimney stenting in redo-TAVI. In a research correspondence, next-day discharge following TAVI via alternative vascular access is discussed. There is also a flashlight on transcaval transcatheter aortic valve implantation via left-sided venous access and a letter to the editor, news from EAPCI; and more...

Flashlight

Jun 16

Left-sided transcaval TAVI

Conor J. Doyle, Ivan P. Casserly

This case report describes a technique to facilitate transcaval transcatheter aortic valve implantation in a patient with an occluded right common iliac vein, using a modified Amplatz left 0.75 guide catheter to achieve successful transcaval access from the left femoral vein.

Editorial

Jun 13

Long-term follow-up of polymer-free DES

Raffaele Piccolo, Ernest Spitzer

The study compared the long-term outcomes of a polymer-free, biolimus-eluting stent and a biodegradable-polymer, sirolimus-eluting stent in 3,151 patients undergoing PCI.

free

Original Research

Jun 12

SORT OUT IX: 5-year results

Lisette Okkels Jensen, Evald Høj Christiansen

The SORT OUT IX trial compared a polymer-free biolimus-eluting stent with a biodegradable-polymer sirolimus-eluting stent in an all-comer PCI population. At 5 years, target lesion failure was similar, but target lesion revascularization was higher with the biolimus-eluting stent.

Original Research

Jun 11

SORT OUT VIII: 5-year follow-up

Nicolaj Brejnholt Støttrup, Michael Maeng

A randomized trial comparing 5-year outcomes of the SYNERGY everolimus-eluting stent and the BioMatrix biolimus-eluting stent, finding comparable target lesion failure but lower myocardial infarction rates with the SYNERGY stent.